Prescient Therapeutics Limited (PSTTF) Discusses EMA Orphan Drug Designation and Clinical Progress of PTX-100 for CTCL Transcript
Source: SeekingAlpha
2025-11-25 03:43:25 ET
Prescient Therapeutics Limited (PSTTF) Discusses EMA Orphan Drug Designation and Clinical Progress of PTX-100 for CTCL November 24, 2025 11:00 PM EST...
Read the full article on Seeking Alpha
For further details see:
Prescient Therapeutics Limited (PSTTF) Discusses EMA Orphan Drug Designation and Clinical Progress of PTX-100 for CTCL Transcript
Prescient Therapeutics Ltd
NASDAQ: PSTTF
PSTTF Trading
100.0% G/L:
$0.145 Last:
100,000 Volume:
$0 Open:
